卖什么
CRISPR powered Diagnostics with results in minutes.
商业模式拆解
买家：谁掌握预算？
未核实Urgent care operators and clinic medical directors (US urgent-care chains and independents).
触发点：什么让他们现在购买？
Up to 4 in 5 urgent-care respiratory patients leave without a definitive answer; antigen tests are inaccurate and lab PCR is slow.
工作流：什么输入变成什么输出？
Swab patient, load single-use cartridge into benchtop instrument, read syndromic panel result in under ten minutes before the patient leaves.
经济账：省了什么，怎么收费？
Instrument plus single-use cartridges for a ~$3B US urgent-care respiratory testing market; product in development, not yet cleared or for sale.
渠道：怎么接触到客户？
Urgent-care channel partnership with UCPMM (300+ centers), led by VedaBio commercial team after anticipated FDA clearance; Siemens Healthineers strategic agreement.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2021 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.